BERKELEY, CA--(Marketwire - October 20, 2010) - Dynavax Technologies Corporation (
Michael Ostrach, Chief Business Officer, will provide a corporate overview at 11:00 am Eastern Time (8:00 am Pacific Time).
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.
Contact Information:
Contact:
Shari Annes
Investor Relations
510-665-7211